Filing Flows › Citius Pharmaceuticals (CTXR) › Stock forecast & fair value
Citius Pharmaceuticals (CTXR) stock forecast and price target
Citius Pharmaceuticals (CTXR) trades at $0.55. One analyst's price target is $4.00 (+634%).
Citius Pharmaceuticals' latest quarter
Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CTXR stock?
One analyst's 12-month target is $4.00, +634% from $0.55. The average rating is none.
Does Citius Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is CTXR stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.